ARTIFICIAL INTELLIGENCE IN TRANSPLANTATION: Edited by Javier BriceñoRecent advances in precision medicine for individualized immunosuppressionFu, Shengyi; Zarrinpar, AliAuthor Information Department of Surgery, College of Medicine, University of Florida, Gainesville, Florida, USA Correspondence to Ali Zarrinpar, Department of Surgery, College of Medicine, University of Florida, Gainesville, FL 32610, USA. Tel: +1 352 265 0606; fax: +1 352 265 0678; e-mail: [email protected] Current Opinion in Organ Transplantation: August 2020 - Volume 25 - Issue 4 - p 420-425 doi: 10.1097/MOT.0000000000000771 Buy Metrics Abstract Purpose of review The current tools to proactively guide and individualize immunosuppression in solid organ transplantation are limited. Despite continued improvements in posttransplant outcomes, the adverse effects of over-immunosuppression or under-immunosuppression are common. The present review is intended to highlight recent advances in individualized immunosuppression. Recent findings There has been a great focus on genomic information to predict drug dose requirements, specifically on single nucleotide polymorphisms of CYP3A5 and ABCB1. Furthermore, biomarker studies have developed ways to better predict clinical outcomes, such as graft rejection. Summary The integration of advanced computing tools, such as artificial neural networks and machine learning, with genome sequencing has led to intriguing findings on individual or group-specific dosing requirements. Rapid computing allows for processing of data and discovering otherwise undetected clinical patterns. Genetic polymorphisms of CYP3A5 and ABCB1 have yielded results to suggest varying dose requirements correlated with race and sex. Newly proposed biomarkers offer precise and noninvasive ways to monitor patient's status. Cell-free DNA quantitation is increasingly explored as an indicator of allograft injury and rejection, which can help avoid unneeded biopsies and more frequently monitor graft function. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.